BRIEF published on 12/08/2025 at 19:35, 2 months 27 days ago ADOCIA Announces Share and Voting Rights Update Voting Rights Shares Financial Disclosure Diabetes Treatment ADOCIA
PRESS RELEASE published on 12/08/2025 at 19:30, 2 months 27 days ago Inside Information / Other news releases Adocia SA releases total number of shares and voting rights as of December 8th, 2025. Company focuses on innovative therapeutic solutions for diabetes and obesity Voting Rights Shares Diabetes Obesity ADOCIA
BRIEF published on 12/04/2025 at 07:35, 3 months 1 day ago ADOCIA Secures €10 Million Fundraising for Growth Shares Fundraising Investment Biopharmaceutical ADOCIA
PRESS RELEASE published on 12/04/2025 at 07:30, 3 months 1 day ago Inside Information / Other news releases Adocia successfully completes a €10 million fundraising through a capital increase. Proceeds to support technology platform development. Cash runway extended to 2027 Fundraising Capital Increase Cash Runway ADOCIA Technology Platforms
BRIEF published on 11/12/2025 at 07:35, 3 months 23 days ago Adocia Progresse with AdoXLongTM and BioChaperone® Diabetes Patent ADOCIA BioChaperone® AdoXLongTM
PRESS RELEASE published on 11/12/2025 at 07:30, 3 months 23 days ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 4 months 15 days ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 4 months 21 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 4 months 21 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 07/25/2025 at 08:50, 7 months 11 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 2 hours 5 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 2 hours 15 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 15:32, 13 minutes ago Correction of a release from 31.12.2025 07:30 GMT/BST - Restoration- daVictus Plc
Published on 03/05/2026 at 15:06, 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 03/04/2026 at 23:50, 15 hours 55 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 21 hours 45 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 22 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
